$FPH

Five Point Holdings reported 3Q 2026 revenue of $14.6M, up 8.4% YoY, and a net loss of $2.6M, compared to a $21.1M profit last year. EPS was $(0.04). Revenue growth was driven by Hearthstone management fees, while Great Park fees declined. The company began infrastructure work at Candlestick and received approval for 3,600 homesites at Valencia.

Five Point (FPH) expects small Q4 net income and $20M for 2026, adjusting land sale expectations. Q3 saw 54 homes sold at Great Park, 92 at Valencia. Cash position: $358.7M, liquidity: $576.2M. CFO Tobler forecasts >$300M cash by 2026, with $125M development spending planned. Management revenue: $13.9M, Hearthstone AUM: $3.4B. Progress reported at Valencia and Candlestick.

Five Point Holdings, LLC (FPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Five Point Holdings, LLC Reports Third Quarter 2026 Results Third Quarter 2026 Highlights • Great Park Venture distributions and incentive compensation payments to the Company totaled $40.4 million. • Great Park builder sales of 54 homes during the quarter. • Valenci

Five Point Holdings, LLC (FPH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 29, 2026, Five Point Holdings, LLC (the “Company”) extended the term of its Development Management Agreement with Heritage Fields El Toro, LLC (“HFET”), the owner of the Great Park Neighborhoods community, throug

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

CSL, Ansell, and Ramsay led the ASX healthcare sector's strong August performance, with gains of 40%, 23.2%, and 16.2% respectively. The sector's total return index rose 44.1% from its June low, outperforming the broader market. Analysts are cautiously optimistic about FY27, but concerns remain about valuation and sustained growth.

New Zealand's S&P/NZX 50 index rose 1.1% on Monday, ending August with a 1.6% monthly gain. Gentrack led gains with a 31% surge after board changes, while Fisher & Paykel Healthcare rose 9.1%. Westpac Banking Corp fell 8.1%. Investors rebalanced portfolios, with Auckland Airport seeing heavy trading. Asian markets were muted, and oil prices climbed after US-Iran tensions.

New Zealand's S&P/NZX 50 index fell 0.7% as Chorus declined 5.3% after its earnings outlook missed expectations, while Fisher & Paykel Healthcare rose 1.6% following upgraded price targets. Infratil dropped 2.1%, and SkyCity Entertainment Group surged 9.9% on potential takeover interest. Asian markets also declined, led by Alibaba's 9.8% drop.

Fisher & Paykel Healthcare upgraded its 2027 guidance, citing strong hospital product sales. Revenue and net profit forecasts increased, with first-half revenue expected at $1.24B and net profit at $280M. The stock closed at $43.52. On Wall Street, the Dow fell 1.32% as bond yields rose and Walmart missed earnings. In NZ, several companies reported earnings, including South Port NZ and Seeka.

Fisher & Paykel Healthcare (FPH) provided first-half FY27 guidance, expecting $1.24B revenue and $280M net profit, up 14% and 24% respectively. Full-year outlook raised to $2.47B-$2.57B revenue and $525M-$565M net profit, including $23M in tariff refunds. Growth driven by strong demand and clinical practice changes.